The ~13% pricing discount signals urgency, likely tied to cash runway for phase 3 IGNYTE-3 confirmatory trial and TUDRIQEV launch costs. Historical long calls on REPL have performed well (63% win rate, +20% avg T+20), but this dilutive offering creates near-term overhang. Monitor for insider lock-up expiry; 45-day period starts after Aug 10 prospectus supplement — first potential unlocking ~Sep 24. If stock trades above $12.06 after close, some hedge unwinding may create volatility.
Price Chart
Executive Summary
Replimune Group priced a $150M underwritten offering of 9.7M common shares at $12.06/share and 2.7M pre-funded warrants at $12.0599/warrant. Estimated net proceeds are approximately $140.5M. The dilutive offering more than doubles the company's cash balance but adds ~18% share overhang, typical for a commercial-stage biotech funding pipeline and commercialization.
Key Facts
- Offering of 9,701,490 common shares + 2,736,340 pre-funded warrants (exercise price $0.0001)
- Aggregate gross proceeds of approximately $150M; estimated net proceeds ~$140.5M
- Offering priced at $12.06 per share, a ~13% discount to the $12.40 opening on Aug 7 pre-filing
- Underwriters: Leerink Partners, J.P. Morgan, Cantor Fitzgerald
- Closing expected August 11, 2026 with customary conditions
- 45-day lock-up on insiders from date of final prospectus supplement
Financial Impact
~$140.5M net proceeds added to cash; 9.7M new shares + 2.7M pre-funded warrant shares = 12.4M total new common-equivalent shares, ~18% dilution on ~69M est. pre-offer shares (assuming ~70M pre-offer)
Risk Factors
- 18% dilution pressures near-term EPS; no revenue data in filing to offset
- No stated use of proceeds detail — investors face uncertainty on cash burn rate allocation
- Pre-funded warrants allow immediate secondary selling at any time (ex $0.0001 exercise), adding overhang
- Biotech sector risk: confirmatory phase 3 data (IGNYTE-3) still pending; offering may signal need for more capital before readout
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-093042 |
| Document: tm2622673d1_ex4-1.htm | 0001104659-26-093042 |
| Document: tm2622673d1_8k.htm | 0001104659-26-093042 |
| Document: tm2622673d1_ex99-1.htm | 0001104659-26-093042 |
| Document: tm2622673d1_ex5-1.htm | 0001104659-26-093042 |
| Document: 0001104659-26-093042-index-headers.html | 0001104659-26-093042 |
| Document: 0001104659-26-093042-index.html | 0001104659-26-093042 |
| Document: 0001104659-26-093042.txt | 0001104659-26-093042 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 5w ago | Press Release | $14.71 $13.07 | ▲ +11.15% | ▲ +11.16% | $13.04 (+11.35%) |
Aug 19, 2026 6w ago | Insider Cluster | $14.05 $13.07 | ▼ −6.98% | ▼ −6.98% | $13.04 (−7.19%) |
Aug 14, 2026 7w ago | 8-K | $14.97 $13.11 | ▼ −12.42% | ▼ −10.43% | $13.04 (−12.89%) |
Aug 14, 2026 7w ago | Press Release | $14.97 $13.11 | ▼ −12.42% | ▼ −10.43% | $13.04 (−12.89%) |
Aug 12, 2026 7w ago | Insider Cluster | $15.19 $12.92 | ▼ −14.94% | ▼ −13.20% | $13.04 (−14.15%) |
Aug 12, 2026 7w ago | Insider Cluster | $15.19 $12.92 | ▼ −14.94% | ▼ −13.20% | $13.04 (−14.15%) |
Aug 10, 2026 7w ago | Press Release | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 10, 2026 7w ago | 8-K | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 10, 2026 7w ago | 424B5 | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 7, 2026 8w ago | 8-K | $12.06 $15.04 | ▲ +24.71% | ▲ +25.11% | $13.04 (+8.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access